Chi T Viet, Gary Yu, Kesava Asam, Carissa M Thomas, Angela J Yoon, Yan Chen Wongworawat, Mina Haghighiabyaneh, Courtney A Kilkuts, Caitlyn M McGue, Marcus A Couey, Nicholas F Callahan, Coleen Doan, Paul C Walker, Khanh Nguyen, Stephanie C Kidd, Steve C Lee, Anupama Grandhi, Allen C Cheng, Ashish A Patel, Elizabeth Philipone, Olivia L Ricks, Clint T Allen, Bradley E Aouizerat
BACKGROUND: Oral squamous cell carcinoma (OSCC) is a capricious cancer with poor survival rates, even for early-stage patients. There is a pressing need to develop more precise risk assessment methods to appropriately tailor clinical treatment. Genome-wide association studies have not produced a viable biomarker. However, these studies are limited by using heterogeneous cohorts, not focusing on methylation although OSCC is a heavily epigenetically-regulated cancer, and not combining molecular data with clinicopathologic data for risk prediction...
June 5, 2021: Biomarker Research